Discover and read the best of Twitter Threads about #blueribbonpanel
Most recents (2)
So many amazing teams, having trouble filling out my #RheumMadness bracket!
2021: I thought the tournament came down to clinical trials vs scientific discoveries
Spoiler alert: clinical trials won (😢)
2022: past vs present vs future?
🧵
2021: I thought the tournament came down to clinical trials vs scientific discoveries
Spoiler alert: clinical trials won (😢)
2022: past vs present vs future?
🧵
Cells region: all about future implication
- NET: hot topic for a while now, but not yet ready for clinical utility
- Cytokine networks: may redefine how we classify rheumatic disease, though not anytime soon
- NET: hot topic for a while now, but not yet ready for clinical utility
- Cytokine networks: may redefine how we classify rheumatic disease, though not anytime soon
CAR-T and Pim kinases: both cancer therapies that can be repurposed for rheumatic disease
Both many years away from routine clinical care, though CAR-T has been successful in severe SLE!
Both many years away from routine clinical care, though CAR-T has been successful in severe SLE!
1/
Let's be honest...
💥💥“THE TISSUE IS THE ISSUE” 💥💥
#Nephropath #NephMadness
This region features:
🔎PLA2R 🆚Other Membranous Antigens
🔎DNAJB9 🆚IgG4 Disease
READY???👇👇
ajkdblog.org/2022/03/01/nep…
Let's be honest...
💥💥“THE TISSUE IS THE ISSUE” 💥💥
#Nephropath #NephMadness
This region features:
🔎PLA2R 🆚Other Membranous Antigens
🔎DNAJB9 🆚IgG4 Disease
READY???👇👇
ajkdblog.org/2022/03/01/nep…
2/
Matchup 1⃣: PLA2R 🆚Other MN Antigens
PLA2R facts
✅Present in healthy human podocytes
✅70-80% 👥with 1ry MN & ~ 60% of ALL MN
✅Serum Ab are measured via ELISA & IF
💡💡DX:
🧪ELISA > 14 RU/mL or
🧪ELISA 2 - 14 RU/mL WITH a positive IFA
pubmed.ncbi.nlm.nih.gov/34556256/
Matchup 1⃣: PLA2R 🆚Other MN Antigens
PLA2R facts
✅Present in healthy human podocytes
✅70-80% 👥with 1ry MN & ~ 60% of ALL MN
✅Serum Ab are measured via ELISA & IF
💡💡DX:
🧪ELISA > 14 RU/mL or
🧪ELISA 2 - 14 RU/mL WITH a positive IFA
pubmed.ncbi.nlm.nih.gov/34556256/
3/
Check this beautiful Visual Abstract by @Vernisartan on the serology based approach to MN
A few more words on Anti-PLA2R titers:
✅>150 RU/mL- ⏫ risk of progression
✅> 45 RU/mL- ⏫risk of recurrence post transplant
💡 Titers are part of the risk stratification algorithm💡
Check this beautiful Visual Abstract by @Vernisartan on the serology based approach to MN
A few more words on Anti-PLA2R titers:
✅>150 RU/mL- ⏫ risk of progression
✅> 45 RU/mL- ⏫risk of recurrence post transplant
💡 Titers are part of the risk stratification algorithm💡
